Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.
idelalisib 150 MG Oral Tablet [Zydelig]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background: Idelalisib (Zydelig®, IDELA), an oral agent, and copanlisib (Aliqopa®, COPA), an intravenous agent, are the only B… Expand
2015
2015
The phosphoinositide 3-kinase (PI3K) family of signalling enzymes play a key role in the transduction of signals from activated… Expand
Review
2015
Review
2015
Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma
Idelalisib (Zydelig®) is a first-in-class, orally administered, phosphatidylinositol 3-kinase-δ inhibitor that was recently… Expand
Highly Cited
2014
Highly Cited
2014
BACKGROUND: There is high unmet need in frail pts with relapsed CLL, particularly in those characterized by adverse prognostic… Expand
Review
2014
Review
2014
Idelalisib (Zydelig®) is a highly specific small-molecule phosphatidylinositol-3-kinase (PI3Kδ) inhibitor that has been developed… Expand
2014
2014
Introduction: PI3Kδ signaling is critical for the proliferation, survival and homing/tissue retention of malignant B cells… Expand
2014
2014
Idelalisib (Zydelig®) is an inhibitor of the B-cell receptor signaling pathway; it is indicated in combination with rituximab in… Expand
